Communiqués Beam Therapeutics Inc.

Actions

BEAM

US07373V1052

Marché Fermé - Nasdaq Autres places de cotation 22:00:01 31/05/2024			Varia. 5j.	Varia. 1 janv.
23,81 ^USD	-1,16 %		-2,10 %	-12,53 %

07/05	Les actions de Beam Therapeutics chutent après que les revenus du premier trimestre aient manqué les estimations	MT
07/05	Beam Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference	30/05	GL
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress	14/05	GL
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference	08/05	GL
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results	07/05	GL
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03	GL
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03	AQ
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02	GL
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02	AQ
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones	27/02	GL
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02	GL
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02	AQ
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors	17/01	AQ
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	08/01	GL
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	02/01	GL
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors	14/12	GL
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results	08/11	GL
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference	08/11	GL
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease	31/10/23	GL
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease	31/10/23	AQ
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT	25/10/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Andy Bromberg, PDG de Beam : Les ETF Bitcoin, une financiarisation éloignée de l'essence originelle de la crypto

Le 30 janvier 2024 à 20:21